Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

NCT00137839 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma
Non-small Cell Lung Cancer

Interventions

DRUG: Erlotinib

Sponsor

Pasi A. Janne, MD, PhD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]